{"filing":{"accession_number":"0001437749-26-020335","cik":"0001005731","ticker":"IDT","company_name":"IDT CORP","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"idt20260611_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1005731/000143774926020335/idt20260611_8k.htm"},"events":[{"id":5450,"run_id":4774,"accession_number":"0001437749-26-020335","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The filing discloses both a director resignation (Irwin Katsof) and a director appointment (William Conkling). While both events are present, the substantive focus and detail center on the appointment of Conkling, including his extensive background in pharmaceutical commercialization, his independence determination, and his committee assignments (Audit Committee Chair and Financial Expert). The resignation is noted as non-contentious and receives minimal disclosure. Director appointments are material to investors assessing board composition and governance.","company_name":"IDT CORP","ticker":"IDT","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6422,"accession_number":"0001437749-26-020335","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a director resignation (Irwin Katsof) and a director appointment (William Conkling). While both events are present, the substantive focus and detail center on the appointment of Conkling, including his extensive background in pharmaceutical commercialization, his independence determination, and his committee assignments (Audit Committee Chair and Financial Expert). The resignation is noted as non-contentious and receives minimal disclosure. Director appointments are material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T21:04:06.160293+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6422,"accession_number":"0001437749-26-020335","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses both a director resignation (Irwin Katsof) and a director appointment (William Conkling). While both events are present, the substantive focus and detail center on the appointment of Conkling, including his extensive background in pharmaceutical commercialization, his independence determination, and his committee assignments (Audit Committee Chair and Financial Expert). The resignation is noted as non-contentious and receives minimal disclosure. Director appointments are material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T21:04:06.160293+00:00","company_name":"IDT CORP","ticker":"IDT","filing_date":"2026-06-11"}]}